Novo Nordisk Intensifies Bid for Obesity Startup Metsera, Challenges Pfizer

Novo Nordisk is escalating its bid for Metsera, an obesity startup, urging Pfizer to increase its offer. CEO Mike Doustdar emphasized the importance of innovation in healthcare during a press conference. This competitive move reflects the growing demand for effective obesity treatments as rates rise globally, marking a significant moment in the weight-loss drug market.